Comentário a «Duração do tratamento com anti-inflamatórios não esteroides e impacto no risco de morte e recorrência de enfarte do miocárdio em pacientes com enfarte do miocárdio prévio. Um estudo de coorte Nacional»

Bombardier, 2000, Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis, N Engl J Med, 343, 1520, 10.1056/NEJM200011233432103 Baron, 2008, Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial, Lancet, 372, 1756, 10.1016/S0140-6736(08)61490-7 Grosser, 2006, Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities, J Clin Invest, 116, 4, 10.1172/JCI27291 Antman, 2007, Taubert. Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association, Circulation, 115, 1634, 10.1161/CIRCULATIONAHA.106.181424